Search:
   

Tuesday, December 11, 2018

Equity Corporate Actions Alert #2018 - 229
Information Regarding the Merger of Keryx Biopharmaceuticals, Inc. (KERX)

Category:

  • Industry Announcement

Markets Impacted:

Contact Information:

Resources:

At a special meeting held December 11, 2018, the shareholders of Keryx Biopharmaceuticals, Inc. (KERX) approved a merger with Akebia Therapeutics Inc. (AKBA). The merger closed today, December 12, 2018. The details are as follows:

Company: Keryx Biopharmaceuticals, Inc.
Issue: Common Stock
CUSIP#: 492515101
Symbol: KERX
Marketplace Effective Date for Suspension: December 13, 2018
Merger Consideration: 0.37433 shares of AKBA per share

Please follow Nasdaq on Facebook RSS and Twitter.

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $13 trillion. To learn more, visit: business.nasdaq.com.

View NASDAQTrader.com Mobile